acetylsalicyclic acid (ASA) — Competitive Intelligence Brief

acetylsalicyclic acid (ASA) (acetylsalicyclic acid (ASA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Cardiovascular.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX Cardiovascular Small molecule

Target snapshot

acetylsalicyclic acid (ASA) (acetylsalicyclic acid (ASA)) — Sanofi. Acetylsalicylic acid (ASA) works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins and thromboxanes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
acetylsalicyclic acid (ASA) TARGET	acetylsalicyclic acid (ASA)	Sanofi	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	COX
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Acetaminophen IV/PO	Acetaminophen IV/PO	The University of Texas Health Science Center, Houston	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes; possibly TRPV1 and other pain pathways
Diclofenac 1%	Diclofenac 1%	Daré Bioscience, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen/acetaminophen	Ibuprofen/acetaminophen	Montefiore Medical Center	marketed	Analgesic/antipyretic combination (NSAID + non-NSAID analgesic)	Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen
Ibuprofen group	Ibuprofen group	University of Salamanca	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class